Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence Meeting Abstract
| Authors: | Bajorin, D. F.; Sharma, P.; Lerner, S. P.; Sims, R. B.; Sanders, A.; DeVries, T.; Sheikh, N. A.; Gomella, L. G. |
| Abstract Title: | Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419601561 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.4547 |
| Notes: | Meeting Abstract: 4547 -- Source: Wos |
